News Releases

- Developing Oral Therapies with Best-in-Class Potential -

Of the Votes Received to Date, More than 98% are Voting in Favor of the Business Combination

Transaction Expected to Create NASDAQ-listed Biopharmaceutical Company Focused on Advancing Immunic‘s Compelling Pipeline of Clinical-Stage and Late Preclinical Assets

Immunic AG gains exclusive, worldwide rights to promising drug development program with novel target for treatment of inflammatory bowel disease

First patient with ulcerative colitis entered the ‘CALDOSE-1’ trial with Immunic’s oral investigational drug IMU-838, a best-in-class DHODH inhibitor

FDA has granted IND approval for Immunic’s oral investigational drug IMU-838

Two phase 1 studies for IMU-838 in healthy volunteers have been completed

Omega and Fund+ broaden Immunic’s investor base and add an additional EUR 10 million (USD 12 million) in equity financing

Series A financing round extended to EUR 21.7 Million